Thr564
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr564  -  PKCI (human)

Site Information
tNEPVQLtPDDDDIV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2839109

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 10 ) , immunoprecipitation ( 10 ) , mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ) , phospho-antibody ( 10 , 16 ) , phosphopeptide mapping ( 21 ) , western blotting ( 10 , 16 )
Disease tissue studied:
brain cancer ( 16 ) , glioblastoma ( 16 ) , glioblastoma multiforme ( 16 ) , glioma ( 16 ) , breast cancer ( 4 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, triple negative ( 3 ) , gastric cancer ( 15 ) , gastric carcinoma ( 15 ) , leukemia ( 14 , 22 ) , acute myelogenous leukemia ( 14 ) , chronic myelogenous leukemia ( 22 ) , lung cancer ( 11 ) , non-small cell lung cancer ( 11 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
PDK1 (human) ( 16 )
Putative in vivo kinases:
PIK3C2A (human) ( 10 )
Treatments:
740-Y-P ( 10 ) , LY294002 ( 16 ) , PKC_inhibitor_myristoylated ( 10 ) , wortmannin ( 10 , 16 )

Downstream Regulation
Effects of modification on biological processes:
signaling pathway regulation ( 10 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Soriano EV, et al. (2016) aPKC Inhibition by Par3 CR3 Flanking Regions Controls Substrate Access and Underpins Apical-Junctional Polarization. Dev Cell 38, 384-98
27554858   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

5

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

6

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

7

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

8

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

9

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

10

Ren SQ, et al. (2013) PKCλ is critical in AMPA receptor phosphorylation and synaptic incorporation during LTP. EMBO J 32, 1365-80
23511975   Curated Info

11

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

12

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

13

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

14

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

15

Mulhern D (2012) CST Curation Set: 13544; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Pp[ST]
Curated Info

16

Desai S, Pillai P, Win-Piazza H, Acevedo-Duncan M (2011) PKC-ι promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway. Biochim Biophys Acta 1813, 1190-7
21419810   Curated Info

17

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

18

Possemato A (2009) CST Curation Set: 7400; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

19

Possemato A (2009) CST Curation Set: 7399; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

20

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

21

Macek B, et al. (2008) Phosphorylation of the human full-length protein kinase Ciota. J Proteome Res 7, 2928-35
18489133   Curated Info

22

Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

23

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

24

Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

25

Messerschmidt A, et al. (2005) Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 352, 918-31
16125198   Curated Info